Plus   Neg

AbbVie, Amgen, Takeda Pharma Enroll First Patients In I-SPY COVID Trial

AbbVie, Inc. (ABBV), Amgen Inc. (AMGN), and Takeda Pharmaceutical Co. Ltd. (TAK) said Monday that they have enrolled the first patients in the I-SPY COVID Trial (Investigation of Serial Studies to Predict Your COVID Therapeutic Response with Biomarker Integration and Adaptive Learning) clinical trial.

The three companies are members of the COVID R&D Alliance, a group of more than 20 of the world's biopharmaceutical and life science companies working to speed the development of novel antibodies, potential therapies and anti-viral therapies for COVID-19.

The I-SPY COVID Trial is a collaboration between members of the COVID R&D Alliance, Quantum Leap, and the U.S. Food and Drug Administration or FDA. The trial is sponsored and managed by Quantum Leap Healthcare Collaborative.

The trial will evaluate the efficacy of cenicriviroc, a chemokine (CCR2 and CCR5) dual-receptor antagonist; Otezla (apremilast), a PDE4 inhibitor; and Firazyr (icatibant injection), a bradykinin B2 receptor antagonist in severely ill, hospitalized COVID-19 patients who require high-flow oxygen.

The I-SPY COVID Trial utilizes Quantum Leap Healthcare Collaborative's adaptive platform trial design, which is intended to increase trial efficiency by minimizing the number of participants and time required to evaluate potential treatments.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pizza Hut's large Original Pan Pizza is now available at locations across the U.S. for $10.99. The fast food chain, a subsidiary of Yum! Brands Inc., said that fans can now get a large Original Pan Pizza with up to three of their favorite toppings, without needing to stretch their wallets. The Original Pan Pizza is a buttery golden-brown color. The U.S. Food and Drug Administration approved the first drug to treat adults and children aged 12 years and older with hypereosinophilic syndrome for six months or longer without another identifiable non-blood related cause of the disease. GlaxoSmithKline's Nucala (mepolizumab) is the first FDA-approved drug in nearly 14 years to treat this group of rare and debilitating blood diseases. Uber has won a legal battle to continue to operate in London, one of its largest markets. The ride-hailing company has been granted an 18-month license to operate in London after overturning the ban on an appeal for the second time. The Westminister Magistrates Court found Uber London Ltd. a "fit and proper" company to run the services in London.
Follow RTT